Response to influenza immunisation in asymptomatic HIV infected men

Mia Huengsberg, Mina P Chakraverty, Gill Cooper, Mohsen Shahmanesh

Abstract

Objective—This study aimed to determine if patients with HIV infection can develop a significant antibody response to influenza immunisation, and whether such immunisation is detrimental to the progression of their HIV illness.

Design—Prospective, non-randomised study.

Methods—The titres of antibody response to influenza immunisation were determined in 44 asymptomatic HIV positive men and compared with 16 HIV presumed seronegative controls. The magnitude of response were correlated with patients’ CD4 lymphocyte counts. The rate of CD4 lymphocyte count decline over a median of 12 months before and after immunisation were also evaluated.

Results—Thirty-two of the 44 HIV positive subjects (73%) were able to mount a four-fold or greater response to at least one of the influenza strains, and 14 of them (32%) did so to all four strains. In comparison, 15 of the 16 controls (93-5%) had a four-fold or greater response to at least one, and six of them (38%) to all influenza strains, which was not significantly different from the HIV positive group. The magnitude of increase in antibody titre was not significantly different between the two groups either. CD4 lymphocyte count change for a median of 12 months after immunisation was not different from a median of 12 months before immunisation.

Conclusions—Asymptomatic HIV infected patients are able to mount antibody response to influenza immunisation, which appears to be safe in respect to HIV illness progression in the short term.

Materials and methods

Study population

Fifty-six asymptomatic (CDC Stage II/III) HIV infected men attending the Genitourinary (GU) Medicine Clinic of Birmingham General Hospital and Birmingham Heartlands Hospital for outpatient follow-up were invited to participate in the study. Forty-four patients were recruited and completed the study. Their median age was 32 years (range 17 to 54); 43 were homosexuals, and one was an intravenous drug user. Their median CD4 count immediately before vaccination was $330 \times 10^3/\text{ml}$ (range 130–1320 $10^3/\text{ml}$). Seventeen of them were taking antiretroviral drugs at the time of the study.

Patients were divided into three groups according to their CD4 lymphocyte count at the beginning of the study: CD4 < 200 $10^3/\text{ml}$ (N = 6), CD4 = 200 – 500 $10^3/\text{ml}$ (N = 23) and CD4 > 501 $10^3/\text{ml}$ (N = 15).

Sixteen male members of staff (including doctors and nurses working in our department and medical students doing GU medicine attachment at the time of the study) were recruited as controls. Their median age was 28 years (range 20 to 51). Fifteen had no known risk factors for HIV infection; one was homosexual who had never practised unsafe sex. HIV test was not performed in this group, as the chance of seropositivity was considered extremely small. None had any known medical illnesses or took long-term medications. Informed consent was obtained from all patients and controls. Side effects were monitored by self-reporting, regular physical examination as well as regular full blood counts, liver and renal function tests were routinely performed.

Introduction

The influenza virus can have devastating effect on public health: in each of the 19 epidemics that occurred in the United States between 1957 and 1986, influenza accounted for more than 10 000 excess deaths.1 Influenza vaccine is 75% effective in preventing complications and death in susceptible individuals.2 Its usage in persons affected by human immunodeficiency virus (HIV) has been recommended by public health advisory bodies of the United States,3 some European countries4 and the United Kingdom.5

Our study aimed to determine if patients with HIV infection develop a significant antibody response to influenza vaccination, whether the antibody response is dependent on T-helper lymphocyte (CD4) count and whether the vaccine adversely affects the patients’ immunity by altering the rate of CD4 decline.
controls were vaccinated with one single intramuscular injection of Influvac (by Duphar) containing 15 μg of each of the influenza viral strains A/Singapore/6/86 H1N1, A/Beijing/353/89 H3N2 and B/Yamagata/16/88. The vaccine was manufactured for the winter of 1992/93. None of the subjects had a history of possible influenza during that season prior to vaccination.

Venous blood was obtained within 4 hours prior to, and 15 to 110 days (median 31.5 days) after Influvac in the patient group, and 27 to 44 days (median 31 days) after Influvac in the control group. Approximately 1 ml of serum was stored at −20°C and transported to PHLS Laboratory in Colindale, London. Antibody levels to each of the above influenza virus strains including B/Panama/45/90 which was the alternative influenza B component recommended by the WHO for the 1992/93 influenza vaccine, were assayed in batches by haemagglutination inhibition against SAD antigen. A four fold rise in antibody titre or a level of 1:40 was considered an adequate response.

Serial CD4 lymphocyte count were obtained according to usual clinical routine in all patients at 3 monthly intervals. All available CD4 lymphocyte count for a median of 12 months before (range 1-17) and 12 months (range 5-17) after the vaccination were collected in all subjects. The rate of CD4 decline was calculated by averaging the mean monthly decline between each separate measured CD4 count.

Statistical analysis
Analysis was performed with median values and fold increase (calculated as the ratio of postvaccination to prevaccination titre) of each of the antibody titres before and after vaccination. Comparison was made between HIV positive patients and staff controls, as well as between patients of different CD4 lymphocyte subgroups. MINITAB statistical software package was utilised; Mann-Whitney U test was performed when comparing median values and chi-square test for proportions.

Table 1 Median fold increase in influenza antibody titre after vaccination

<table>
<thead>
<tr>
<th></th>
<th>CD4 ≤ 200</th>
<th>CD4 200-500</th>
<th>CD4 ≤ 500</th>
<th>Normal</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N = 6</td>
<td>N = 23</td>
<td>N = 15</td>
<td>N = 16</td>
</tr>
<tr>
<td>Singapore</td>
<td>2-0</td>
<td>2-0</td>
<td>2-0</td>
<td>0-0</td>
</tr>
<tr>
<td>(2-0-3-3)</td>
<td>(2-0-3-1)</td>
<td>(2-75-13-0)</td>
<td>(2-6-9-0)</td>
<td></td>
</tr>
<tr>
<td>Beijing</td>
<td>4-0</td>
<td>4-0</td>
<td>4-0</td>
<td>0-0</td>
</tr>
<tr>
<td>(1-0-23-4)</td>
<td>(2-0-12-4)</td>
<td>(2-0-6-0)</td>
<td>(4-0-32-0)</td>
<td></td>
</tr>
<tr>
<td>Yamagata</td>
<td>3-0</td>
<td>3-0</td>
<td>3-0</td>
<td>0-0</td>
</tr>
<tr>
<td>(1-4-17-7)</td>
<td>(2-0-12-0)</td>
<td>(2-0-8-0)</td>
<td>(1-0-19-8)</td>
<td></td>
</tr>
<tr>
<td>Panama</td>
<td>3-0</td>
<td>4-0</td>
<td>4-0</td>
<td>0-0</td>
</tr>
<tr>
<td>(2-0-6-7)</td>
<td>(2-0-8-0)</td>
<td>(2-0-8-0)</td>
<td>(2-0-16-0)</td>
<td></td>
</tr>
</tbody>
</table>

Figures in brackets show 95% confidence interval (1-Sample Sign Confidence Interval); asterisk indicates result significantly different from control group (Mann-Whitney U Test: W = 163-5; p = 0.004).

Table 2 Median antibody titre achieved after influenza vaccination

<table>
<thead>
<tr>
<th></th>
<th>CD4 ≤ 200</th>
<th>CD4 200-500</th>
<th>CD4 ≤ 500</th>
<th>Normal</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N = 6</td>
<td>N = 23</td>
<td>N = 15</td>
<td>N = 16</td>
</tr>
<tr>
<td>Singapore</td>
<td>80-0</td>
<td>160-0</td>
<td>160-0</td>
<td>160-0</td>
</tr>
<tr>
<td>(80-0-468-6)</td>
<td>(80-0-160-0)</td>
<td>(80-0-200-2)</td>
<td>(160-0-320-0)</td>
<td></td>
</tr>
<tr>
<td>Beijing</td>
<td>0-0</td>
<td>40-0</td>
<td>40-0</td>
<td>0-0</td>
</tr>
<tr>
<td>(10-0-160-0)</td>
<td>(20-0-200-0)</td>
<td>(20-0-80-0)</td>
<td>(120-0-640)</td>
<td></td>
</tr>
<tr>
<td>Yamagata</td>
<td>40-0</td>
<td>80-0</td>
<td>80-0</td>
<td>0-0</td>
</tr>
<tr>
<td>(20-0-117-0)</td>
<td>(40-0-160-0)</td>
<td>(20-0-80-0)</td>
<td>(40-0-320-0)</td>
<td></td>
</tr>
<tr>
<td>Panama</td>
<td>40-0</td>
<td>80-0</td>
<td>80-0</td>
<td>0-0</td>
</tr>
<tr>
<td>(20-0-80-0)</td>
<td>(40-0-124-2)</td>
<td>(20-0-80-0)</td>
<td>(20-0-16-0)</td>
<td></td>
</tr>
</tbody>
</table>

Figures in brackets show 95% confidence interval (1-Sample Sign Confidence Interval); asterisk indicates result significantly different from control group (Mann-Whitney U Test: W* = 41-0; p = 0.04; tW = 171-0; p = 0.007).

Results
Thirty-two of the 44 HIV positive subjects (73%) were able to mount a four-fold or more response to at least one of the virus strains, and 14 of them (32%) did so to all four strains. In comparison, 15 of the 16 controls (93.5%) had a four-fold or more response to at least one, and six (25%) of them to all strains. Twenty two (50%) of the patients and 10 (63%) of controls achieved a titre of 1:40 to all four strains of antigens after immunisation, a level considered protective against influenza. Though showing a slight trend towards better response in the control group, the differences were not statistically significant.

The median CD4 lymphocyte count of the patients was 330 × 10^6/ml (130 - 1320 × 10^6/ml) immediately before and 350 × 10^6/ml 10 – 950 × 10^6/ml 3 months post vaccination. CD4 lymphocyte counts before (median of 3, range 1-9 samples) and after (median of 4, range 1-11 samples) immunisation were analysed. The median rate of CD4 lymphocyte decline was calculated as 1.3 × 10^6/ml (mean - 2.9; SD 28-5; SE 6-1; range -123 to 65) per month prior to Influvac injection, and 2.65 × 10^6/ml (mean 6-61; SD 21-1; SE 5-1; range -33 to 75) per month after the injection. The difference was not significant (Mann-Whitney U test: W = 2023-0, p = 0-11). Analysis of the square roots of mean CD4 lymphocyte decline also failed to show any difference before and after immunisation.

Influvac was well tolerated by patients and controls without major side effects. No patients died within 6 months of receiving the vaccination.

Discussion
This study demonstrates that asymptomatic HIV positive patients are able to mount adequate antibody response to influenza vaccine. Seventy-three percent of HIV positive patients were able to mount a four-fold or more antibody response to at least one of the four influenza antigens, and 50% achieve protec-
tive antibody response to all vaccinated strains.

When compared with immunocompetent controls, HIV positive patients seem to mount a lower antibody response after vaccination. However, the difference was not statistically significant in all but one strain. We were unable to detect even a trend towards higher antibody response in patients with good CD4 count compared with those with low CD4 count. This is in contrast to the study by Kroon et al. who reported that antibody response in HIV patients seemed to correlate with their CD4 count. However, unlike Kroon’s study, our patient group did not include those with CD4 lymphocyte count less than 100 × 10⁶/ml.

Even though the timing of testing for antibody response after vaccination varied between individuals (range 15–110 days), we do not feel that this has significantly influenced our results. Influvac antibody response is expected to occur within 2 weeks after vaccination and remain stable for at least six months.

This study did not address the question of clinical efficacy of the vaccine. Cost-effective analysis has shown that routine recommendation of influenza immunisation to HIV infected patients is a less efficient policy compared with pneumococcal vaccination, as the case fatality of pneumonia is lower, immunodeficiency only minimally increases the risk of contracting influenza, and vaccination is necessary annually. However, influenza can predispose to bacterial pneumonia in immunocompetent adults; in immunocompromised patients, symptoms may be prolonged and risk of complications increased.

In the United States, up to a third of HIV infected adolescents and adults receive influenza vaccination. This study, together with others, has shown that if influenza immunisation is considered appropriate is a particular individual, adequate antibody response can be expected in asymptomatic patients, especially if the CD4 lymphocyte count is > 100 × 10⁶/ml.

Our study confirms the safety of the influenza vaccine. We were unable to demonstrate any deleterious effect of the vaccine on the course of HIV infection as evidenced by our observation on CD4 lymphocyte count. Three months after immunisation, there was no change in the mean CD4 lymphocyte count. A median of 12 months later, the rate of CD4 lymphocyte decline was not different from that prior to immunisation. This confirms findings of other studies which showed no unexpected change in CD4 lymphocyte count after influenza immunisation.

We thank Dr E Boxall, Dr S Skidmore and Mrs Julie King of Regional Virus Laboratory, Birmingham Heartlands Hospital for their assistance in handling and transporting the serum samples.

This study was not formally considered by the University of Birmingham Research Ethics Committee. However, the project was discussed with the Chairman, who gave his verbal approval of the study.

6 Centres for Disease Control: Revision of the CDC surveillance case-definition for acquired immunodeficiency syndrome. MMWR 1987;36(suppl):1S–15S.
Response to influenza immunisation in asymptomatic HIV infected men.

M Huengsberg, M P Chakraverty, G Cooper and M Shahmanesh

*Genitourin Med* 1995 71: 355-357
doi: 10.1136/sti.71.6.355

Updated information and services can be found at:
http://sti.bmj.com/content/71/6/355

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**